PubMed · 2013 · 12 citations · 39 references
Life SciencesCell BiologyOncologyApoptosisMolecular OncologyNeoplasiaApoptosis In CancerApoptosis RegulationApoptotic SignalingBcl-2 Family ProteinsCell DeathGastric CancerApoptosis-inducing FactorBcl-2 InhibitionBcl-2 Protein ExpressionCancer Cell ApoptosisP53 MutationP53-mediated ApoptosisPathology Of Gastric CancerTumor Suppressor P53
PURPOSE: Gastric cancer is a biologically heterogeneous disease containing many genetic and epigenetic alterations. In our study, the expression status of apoptosis-inducing p53 and apoptosis-inhibiting Bcl-2 in gastric cancer and their relation with prognosis, if any, was investigated. METHODS: Patients that were being followed in our clinic and had histopathologically diagnosed gastric adenocarcinoma were included in this study. The p53 and bcl-2 expressions were investigated immunohistochemically and patients were grouped according to p53 and Bcl-2 expression as follows: group A: both p53 and Bcl-2 negative; group B: p53 positive and Bcl-2 negative; group C: p53 negative and Bcl-2 positive; group D: both p53 and Bcl-2 positive. RESULTS: In 19 (51.4%) patients positive immunostaining with p53 was observed, while negative in 18 (48.6%). A significant relationship between the metastatic ability of the tumor and p53 expression was determined (p=0.004). In 78.6% of the metastatic tumors no p53 expression was observed, while in 69.6% of the non-metastatic tumors p53 expression was positive. No significant relationship was detected between p53 expression and survival. Positive immunostaining with Bcl-2 was observed in 9 (16.7%) patients, and negative in 45 (83.3%). No significant relationship was determined between the Bcl-2 expression and the depth of invasion, dissemination to lymph nodes and metastatic ability of the tumor. A borderline statistically significant relationship was determined between the Bcl-2 expression and survival (p=0.051). Group B patients showed a statistically significant survival difference compared with the other groups (p=0.022). CONCLUSION: The results of this study suggest that concurrent evaluation of p53 and Bcl-2 in patients with gastric adenocarcinoma may have prognostic importance.
39
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
Ian Chau, Andy Norman, David Cunningham et al. · Journal of Clinical Oncology · 2004 · 531 citations
Medicine, Oncology, Chemotherapy +14
Down-regulation of bcl-2 by p53 in breast cancer cells.
Subrata Haldar, Massimo Negrini, Maria Monne et al. · PubMed · 1994 · 479 citations
p53 expression and prognosis in gastric carcinoma
Hilary M. Martin, M. I. Filipe, Richard Morris et al. · International Journal of Cancer · 1992 · 329 citations